Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cosmo Bio Co., Ltd. (3386:JPX), powered by AI.
Cosmo Bio Co., Ltd. is currently trading at ¥1,264. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cosmo Bio Co., Ltd. on Alpha Lenz.
Cosmo Bio Co., Ltd.'s P/E ratio is 28.1.
“Cosmo Bio Co., Ltd. trades at a P/E of 28.1 (premium valuation) with modest ROE of 3.0%.”
Ask for details →Cosmo Bio Co., Ltd. is a Japanese company specializing in the distribution and sale of life science products and services. It plays a crucial role in the biotechnology sector by providing essential research materials and laboratory supplies. The company's primary function is to support scientific research and development, particularly in the fields of medical and biological research. Cosmo Bio Co., Ltd. offers a diverse range of products, including antibodies, enzymes, assay kits, and cell culture media, catering to the needs of researchers and institutions engaged in various scientific endeavors. Significantly, Cosmo Bio is instrumental in facilitating advancements in healthcare and biotechnology through its extensive product catalog. It serves multiple industries, including pharmaceuticals, universities, environmental research, and diagnostic laboratories. By enabling access to high-quality, innovative research tools, Cosmo Bio Co., Ltd. supports groundbreaking work in areas such as disease understanding, drug development, and genetic research. Situated in a competitive market, the company remains a pivotal figure in the Japanese life sciences supply chain, contributing to the advancement of scientific knowledge and the improvement of health outcomes globally.
“Cosmo Bio Co., Ltd. trades at a P/E of 28.1 (premium valuation) with modest ROE of 3.0%.”
Ask for details →Cosmo Bio Co., Ltd. (ticker: 3386) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 174 employees. Market cap is $7.4B.
The current price is 1,264 with a P/E ratio of 28.06x and P/B of 0.82x.
ROE is 3.01% and operating margin is 3.18%. Annual revenue is $10.0B.